MX367614B - Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma. - Google Patents
Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma.Info
- Publication number
- MX367614B MX367614B MX2014008751A MX2014008751A MX367614B MX 367614 B MX367614 B MX 367614B MX 2014008751 A MX2014008751 A MX 2014008751A MX 2014008751 A MX2014008751 A MX 2014008751A MX 367614 B MX367614 B MX 367614B
- Authority
- MX
- Mexico
- Prior art keywords
- dianhydrogalactitol
- medulloblastoma
- stem cells
- cancer stem
- multforme
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1007—Arrangements or means for the introduction of sources into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
- A61N2005/1024—Seeds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
El uso de dianhidrogalactitol proporciona una modalidad terapéutica novedosa para el tratamiento de glioblastoma multiforme y meduloblastoma. El dianhidrogalactitol actúa como un agente alquilante en el ADN que crea la metilación en N7. El dianhidrogalactitol es efectivo en suprimir el crecimiento de células madre de cáncer y es activo en contra de tumores que son refractarios a temozolomida; el fármaco actúa independientemente del mecanismo de reparación de MGMT.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261589029P | 2012-01-20 | 2012-01-20 | |
PCT/US2013/022505 WO2013110058A2 (en) | 2012-01-20 | 2013-01-22 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014008751A MX2014008751A (es) | 2016-01-08 |
MX367614B true MX367614B (es) | 2019-08-28 |
Family
ID=48799821
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014008751A MX367614B (es) | 2012-01-20 | 2013-01-22 | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma. |
MX2019002917A MX2019002917A (es) | 2012-01-20 | 2014-07-18 | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019002917A MX2019002917A (es) | 2012-01-20 | 2014-07-18 | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma. |
Country Status (14)
Country | Link |
---|---|
US (6) | US10201521B2 (es) |
EP (1) | EP2804602A4 (es) |
JP (4) | JP2015511936A (es) |
KR (3) | KR20220137154A (es) |
CN (4) | CN110711188A (es) |
AU (3) | AU2013209394A1 (es) |
BR (1) | BR112014017833A2 (es) |
CA (1) | CA2862706C (es) |
CL (1) | CL2014001917A1 (es) |
HK (1) | HK1208365A1 (es) |
IL (2) | IL233722B (es) |
MX (2) | MX367614B (es) |
SG (1) | SG11201404216TA (es) |
WO (1) | WO2013110058A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014081405A2 (en) * | 2011-08-17 | 2014-05-30 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
CN110711188A (zh) * | 2012-01-20 | 2020-01-21 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
US11491154B2 (en) * | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
TW201536278A (zh) * | 2013-05-31 | 2015-10-01 | Del Mar Pharmaceuticals | 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途 |
US20160067241A1 (en) * | 2013-06-13 | 2016-03-10 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
US20190015379A1 (en) * | 2014-11-10 | 2019-01-17 | Delmar Pharmaceuticals, Inc. | Use of dianhydrogalactitol and analogs and derivatives thereof, together with radiation, to treat non-small-cell carcinoma of the lung and glioblastoma multiforme and suppress proliferation of cancer stem cells |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9375478B1 (en) | 2015-01-30 | 2016-06-28 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
CA2989420A1 (en) | 2015-06-16 | 2016-12-22 | Targent, Llc | New crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol |
WO2017042634A2 (en) * | 2015-09-10 | 2017-03-16 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol or derivatives and analogs thereof for treatment of non-small-cell lung carcinoma, glioblastoma, and ovarian carcinoma by induction of dna damage and stalling of cell cycle |
US11446274B2 (en) | 2015-10-28 | 2022-09-20 | Del Mar Pharmaceuticals (Bc) Ltd. | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies |
CN105663076A (zh) * | 2016-02-23 | 2016-06-15 | 广西梧州制药(集团)股份有限公司 | 一种起效快防潮好的去水卫矛醇薄膜包衣片及其制备方法 |
CN105663072B (zh) * | 2016-02-23 | 2018-09-28 | 广西梧州制药(集团)股份有限公司 | 一种去水卫矛醇薄膜包衣片及其制备方法 |
CN105663060B (zh) * | 2016-02-23 | 2018-08-14 | 广西梧州制药(集团)股份有限公司 | 一种去水卫矛醇脂质体冻干粉针剂及其制备方法 |
CN105663075B (zh) * | 2016-02-23 | 2018-09-14 | 广西梧州制药(集团)股份有限公司 | 一种二溴卫矛醇肠溶片及其制备方法 |
US20190133980A1 (en) * | 2016-06-02 | 2019-05-09 | Yale University | Compositions and methods for targeting and treating homologous recombination-deficient tumors |
US20200062839A1 (en) * | 2017-05-01 | 2020-02-27 | Del Mar Pharmaceuticals (Bc) Ltd. | Use of dianhydrogalactitol or analogs and derivatives in combination with vegf inhibitors to treat cancer |
WO2018204412A1 (en) * | 2017-05-01 | 2018-11-08 | Thomas Jefferson University | Systems-level analysis of tcga cancers reveals disease trna fragmentation patterns and associations with messenger rnas and repeat |
JP7254780B2 (ja) * | 2017-09-20 | 2023-04-10 | オクラホマ・メディカル・リサーチ・ファウンデーション | 薬剤耐性神経膠腫の治療法 |
WO2019106424A1 (en) * | 2017-12-01 | 2019-06-06 | Del Mar Pharmaceuticals (Bc) Limited | Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas |
JP2021512921A (ja) * | 2018-02-12 | 2021-05-20 | メディシノバ・インコーポレイテッドMediciNova, Inc. | 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン |
US11311538B2 (en) | 2018-07-13 | 2022-04-26 | Yale University | Compositions and methods for targeting cancers |
KR102130501B1 (ko) * | 2019-06-12 | 2020-07-07 | 브렉소젠 주식회사 | 테트란드린을 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포능 증가용 조성물 |
CN110283047A (zh) * | 2019-07-11 | 2019-09-27 | 夏永刚 | 单糖部分甲基化阿尔迪醇乙酸酯的合成方法 |
EP4297746A2 (en) * | 2021-02-23 | 2024-01-03 | Edison Oncology | Compositions and methods to improve the therapeutic benefit of suboptimally administered compounds and therapies for the treatment of diseases |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5294430A (en) | 1988-09-12 | 1994-03-15 | University Of Rochester | Use of dithiocarbamates to treat myelosuppression |
US5035878A (en) | 1988-09-12 | 1991-07-30 | University Of Rochester | Use of dithiocarbamates to counteract myelosuppression |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US6287792B1 (en) | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
US6011069A (en) | 1995-12-26 | 2000-01-04 | Nisshin Flour Milling Co., Ltd. | Multidrug resistance inhibitors |
US5789700A (en) | 1996-01-19 | 1998-08-04 | Young; J. Ronald | Grounding device with mounting brackets |
EP1085846A2 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
WO2000002555A1 (en) | 1998-07-09 | 2000-01-20 | Nardella Francis A | Methods and compositions for the treatment of chronic lymphocytic leukemia |
WO2001007084A1 (en) | 1999-07-23 | 2001-02-01 | Regents Of The University Of California | Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
US6322828B1 (en) | 1999-09-13 | 2001-11-27 | Deseret Laboratories, Inc. | Process for manufacturing a pharmaceutical chewing gum |
US6372250B1 (en) | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
US6921722B2 (en) | 2000-05-30 | 2005-07-26 | Ebara Corporation | Coating, modification and etching of substrate surface with particle beam irradiation of the same |
US20020037328A1 (en) * | 2000-06-01 | 2002-03-28 | Brown Dennis M. | Hexitol compositions and uses thereof |
CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
US7619005B2 (en) | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
PT1397155E (pt) | 2001-06-21 | 2015-12-07 | Genentech Inc | Formulação de libertação sustentada |
AU2003219796A1 (en) | 2002-02-20 | 2003-09-09 | Beth Israel Deaconess Medical Center | Conjugates comprising a biodegradable polymer and uses therefor |
US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
WO2008106408A1 (en) | 2007-02-27 | 2008-09-04 | Cedars-Sinai Medical Center | Treatment of cancer with bio and chemotherapy |
US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
EP1589943A2 (en) * | 2003-01-09 | 2005-11-02 | Arizeke Pharmaceuticals, Inc. | Methods of treating lung diseases |
NZ567952A (en) | 2003-03-24 | 2009-12-24 | Sequoia Pharmaceuticals Inc | Long acting biologically active conjugates |
EP1462119A1 (en) | 2003-03-24 | 2004-09-29 | Schering AG | Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics |
ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
MXPA06002499A (es) | 2003-09-04 | 2006-06-20 | Aventis Pharma Inc | Indoles sustituidos como inhibidores de poli (adp-ribosa) polimerasa (parp). |
JP2007505634A (ja) | 2003-09-22 | 2007-03-15 | ロゼッタ インファーマティクス エルエルシー | Rna干渉を用いる合成致死スクリーニング |
EP1673373A2 (en) | 2003-10-02 | 2006-06-28 | Salmedix, Inc. | Indole derivatives |
HUP0303313A2 (hu) | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
WO2005058816A1 (de) | 2003-12-18 | 2005-06-30 | Salama Zoser B | Prolinderivate als pharmazeutische wirkstoffe in der tumortherapie |
EP1708712A1 (en) * | 2003-12-24 | 2006-10-11 | Scios, Inc. | Treatment of malignant gliomas with tgf-beta inhibitors |
US7754897B2 (en) | 2005-06-15 | 2010-07-13 | Cardiome Pharma Corp. | Synthetic processes for the preparation of aminocyclohexyl ether compounds |
EA012416B1 (ru) | 2004-06-30 | 2009-10-30 | Янссен Фармацевтика Н.В. | Производные замещенного 2-алкилхиназолинона как ингибиторы parp |
JP5201995B2 (ja) | 2005-01-19 | 2013-06-05 | エーザイ インク. | ジアザベンゾ[デ]アントラセン−3−オン化合物、及び、parpの阻害方法 |
WO2006091587A2 (en) * | 2005-02-22 | 2006-08-31 | Cedars-Sinai Medical Center | Use of minoxidil sulfate as an anti-tumor drug |
US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
ES2370054T3 (es) | 2005-08-24 | 2011-12-12 | Bristol-Myers Squibb Company | Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico. |
US8124095B2 (en) | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
US8324175B2 (en) * | 2006-02-16 | 2012-12-04 | Young Hee Ko | Compositions and methods for the treatment of cancer |
WO2007149907A2 (en) | 2006-06-20 | 2007-12-27 | Abbott Laboratories | Pyrazoloquinazolinones as parp inhibitors |
WO2008016664A2 (en) * | 2006-08-02 | 2008-02-07 | University Of Massachusetts Lowell | Compositions and methods for treating cancer with dacarbazine nanoemulsions |
CA2661842C (en) | 2006-09-01 | 2017-08-22 | Cylene Pharmaceuticals, Inc. | Tricyclic heteroaryl compounds and their use as serine-threonine protein kinases and parp modulators |
US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
CA2677046A1 (en) | 2007-02-28 | 2008-09-04 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
US7820684B2 (en) * | 2007-03-01 | 2010-10-26 | Supergen, Inc. | Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same |
US20100167939A1 (en) * | 2007-03-02 | 2010-07-01 | Kenneth Aldape | Multigene assay to predict outcome in an individual with glioblastoma |
EP2134691B1 (en) | 2007-03-08 | 2012-01-25 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as parp and tank inhibitors |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
GB0710536D0 (en) | 2007-06-01 | 2007-07-11 | Veritron Ltd | Plant extract and its therapeutic use |
ES2514517T3 (es) | 2007-08-10 | 2014-10-28 | Mitsubishi Tanabe Pharma Corporation | Nueva sal de compuesto de isoquinolina y cristal de la misma |
EP2220073B1 (en) | 2007-11-15 | 2014-09-03 | MSD Italia S.r.l. | Pyridazinone derivatives as parp inhibitors |
EP2224804A4 (en) | 2007-12-07 | 2011-06-01 | Bipar Sciences Inc | TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS |
EP2247600A4 (en) | 2008-02-06 | 2011-09-14 | Biomarin Pharm Inc | BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) |
US20090318561A1 (en) | 2008-06-23 | 2009-12-24 | Mutual Pharmaceutical Company, Inc. | Colchicine products, method of manufacture, and methods of use |
CA2730377C (en) | 2008-07-11 | 2017-09-19 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
EP2323664B1 (en) | 2008-07-29 | 2015-01-07 | Nerviano Medical Sciences S.r.l. | Use of a cdk inhibitor for the treatment of glioma |
PT2326650E (pt) | 2008-08-06 | 2014-05-06 | Biomarin Pharm Inc | Inibidores de di-hidropiridoftalazinona de poli(adpribose) polimerase (parp) |
DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
US7928105B2 (en) | 2009-01-23 | 2011-04-19 | Takeda Pharmaceutical Company Limited | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones |
US8323270B2 (en) * | 2009-10-19 | 2012-12-04 | Pharmaco-Kinesis Corporation | Enhanced method for delivering bevacizumab (avastin) into a brain tumor using an implanted magnetic breather pump |
EP2605650A4 (en) | 2010-08-18 | 2014-05-21 | Del Mar Pharmaceuticals | COMPOSITIONS AND METHODS FOR IMPROVING PROFIT TREATMENT OF CHEMICAL COMPOUNDS IN ADMINISTRATION WAY SUB-OPTIMAL INCLUDING hexitols SUBSTITUTED AS DIANHYDROGALACTITOL COMPOSITIONS AND DIACÉTYLDIANHYDROGALACTITOL AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF CHEMICAL COMPOUNDS IN ADMINISTRATION WAY SUB-OPTIMAL AS DIANHYDROGALACTITOL AND DIACÉTYLDIANHYDROGALACTITOL |
US9901563B2 (en) | 2013-03-11 | 2018-02-27 | Delmar Pharmaceuticals, Inc. | Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
WO2014081405A2 (en) * | 2011-08-17 | 2014-05-30 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol |
CN110711188A (zh) | 2012-01-20 | 2020-01-21 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
CN203476250U (zh) | 2013-04-08 | 2014-03-12 | 山特维克知识产权股份有限公司 | 钻杆挂架 |
-
2013
- 2013-01-22 CN CN201910649595.6A patent/CN110711188A/zh active Pending
- 2013-01-22 CN CN202211319179.8A patent/CN115813902A/zh active Pending
- 2013-01-22 CN CN202211320632.7A patent/CN115778934A/zh active Pending
- 2013-01-22 KR KR1020227033441A patent/KR20220137154A/ko not_active Application Discontinuation
- 2013-01-22 MX MX2014008751A patent/MX367614B/es active IP Right Grant
- 2013-01-22 EP EP13738207.3A patent/EP2804602A4/en active Pending
- 2013-01-22 BR BR112014017833-0A patent/BR112014017833A2/pt not_active Application Discontinuation
- 2013-01-22 KR KR1020217012517A patent/KR20210048608A/ko active Application Filing
- 2013-01-22 US US14/373,552 patent/US10201521B2/en active Active
- 2013-01-22 AU AU2013209394A patent/AU2013209394A1/en not_active Abandoned
- 2013-01-22 CN CN201380015319.5A patent/CN104427984A/zh active Pending
- 2013-01-22 KR KR1020147023300A patent/KR20150018765A/ko active Application Filing
- 2013-01-22 CA CA2862706A patent/CA2862706C/en active Active
- 2013-01-22 SG SG11201404216TA patent/SG11201404216TA/en unknown
- 2013-01-22 JP JP2014553513A patent/JP2015511936A/ja active Pending
- 2013-01-22 WO PCT/US2013/022505 patent/WO2013110058A2/en active Application Filing
-
2014
- 2014-04-04 US US14/245,738 patent/US9687466B2/en active Active
- 2014-07-18 CL CL2014001917A patent/CL2014001917A1/es unknown
- 2014-07-18 MX MX2019002917A patent/MX2019002917A/es unknown
- 2014-07-20 IL IL233722A patent/IL233722B/en unknown
-
2015
- 2015-09-17 HK HK15109103.8A patent/HK1208365A1/xx unknown
-
2017
- 2017-06-08 US US15/617,756 patent/US20170266150A1/en not_active Abandoned
- 2017-10-24 AU AU2017251718A patent/AU2017251718B2/en active Active
-
2018
- 2018-03-01 JP JP2018036393A patent/JP2018109051A/ja active Pending
-
2019
- 2019-01-08 US US16/242,752 patent/US11234955B2/en active Active
- 2019-08-01 AU AU2019210610A patent/AU2019210610B2/en active Active
-
2020
- 2020-09-07 JP JP2020149644A patent/JP2021004244A/ja active Pending
-
2021
- 2021-08-26 IL IL285905A patent/IL285905A/en unknown
-
2022
- 2022-01-24 US US17/583,141 patent/US20220142966A1/en not_active Abandoned
- 2022-03-08 US US17/689,467 patent/US20220193024A1/en not_active Abandoned
- 2022-12-23 JP JP2022206899A patent/JP2023040074A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019002917A (es) | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma. | |
MX340290B (es) | Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación. | |
MX2016013027A (es) | Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario. | |
MX2017006076A (es) | Dianhidrogalactitol junto con radiacion, para tratar carcinoma de pulmón de celulas no pequeñas y glioblastoma multiforme. | |
PH12018502731A1 (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
NZ745556A (en) | Androgen receptor modulator and uses thereof | |
MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
CR20140108A (es) | Compuesto de ciclopropanoamina | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
AR082340A1 (es) | Metodos y composiciones para la terapia del cancer de higado | |
UA108618C2 (uk) | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
IN2012DN06720A (es) | ||
PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
PH12014502046B1 (en) | Treatment of cancer with tor kinase inhibitors | |
WO2012009703A3 (en) | Targeted nanoparticles for cancer and other disorders | |
PH12015500867B1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
BR112012009388A2 (pt) | derivados de apogossipolone como agentes anticâncer | |
TW201613599A (en) | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
GB2527477A (en) | Tumour Therapy | |
TN2013000336A1 (en) | 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy. | |
BRPI0916230A2 (pt) | antagonistas de rna que tem como alvo a gli2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |